Presented by Melody Hartzler, PharmD | March 11, 2026 at 12 PM Pacific

Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, yet traditional lipid panels frequently fail to capture key drivers of cardiometabolic risk. This case-based, evidence-anchored session equips clinicians with practical strategies to interpret and act on the Doctor's Data Cardiometabolic Profile, integrating traditional lipid markers with advanced biomarkers of glycemic control, insulin resistance, inflammation, oxidative stress, adipose signaling, renal function, and lipoprotein physiology.

Through real-world patient cases, participants will learn how to interpret markers including Apolipoproteins A1 and B, small dense LDL, oxidized LDL, PLAC® (Lp-PLA₂ activity), Lipoprotein(a), hs-CRP, homocysteine, insulin, glucose, 1,5-anhydroglucitol (1,5-AG), leptin, adiponectin, the leptin-to-adiponectin ratio, cystatin C, creatinine/eGFR, and comprehensive cholesterol fractions to uncover cardiometabolic risk that extends beyond LDL-centric models.

The session emphasizes pattern recognition and protocol-driven care, translating biomarker abnormalities into targeted lifestyle, nutraceutical, and-when appropriate-pharmacologic strategies aimed at improving metabolic flexibility, vascular health, and long-term cardiovascular outcomes.

Upon completion, participants will be able to:

• Describe the clinical relevance of advanced cardiometabolic biomarkers, including apolipoproteins (A1 and B), small dense LDL, oxidized LDL, PLAC® activity, Lipoprotein(a), inflammatory markers (hs-CRP, homocysteine), glycemic and insulin resistance markers (glucose, insulin, 1,5-AG), adipokines (leptin, adiponectin, leptin-to-adiponectin ratio), and renal markers (cystatin C, creatinine/eGFR), and how they complement traditional lipid testing.
• Interpret real patient case data from the Doctor's Data Cardiometabolic Risk Profile to identify patterns consistent with atherogenic dyslipidemia, metabolic dysfunction, adipose signaling imbalance, oxidative stress, and systemic inflammation.
• Apply evidence-based interventions tailored to specific biomarker abnormalities, including lifestyle and nutrition protocols, physical activity strategies, weight management approaches, targeted supplementation, and appropriate medication considerations when indicated.
• Construct individualized cardiometabolic care plans that integrate advanced biomarker findings with traditional lipid values and established cardiovascular risk frameworks to more precisely assess and mitigate patient risk.

Presented by Julia Malkowski, ND, DC | April 1, 2026 at 12 PM Pacific

Methylation is a fundamental biochemical process with far-reaching implications for human health. This presentation will offer an in-depth exploration of methylation, its clinical significance, and the impact of methylation imbalances on health outcomes.

Methylation is involved in cardiovascular health, detoxification, neurotransmitter synthesis, hormone metabolism, DNA expression, immune modulation and fetal development. Analyzing key methylation biomarkers provides valuable insight into human physiology. Plasma levels of methionine, s-Adenosyl methionine (SAM), s-Adenosyl homocysteine (SAH), homocysteine, cystathionine and cysteine provide a functional assessment of the methylation cycle. Attendees will walk away with an understating of these biomarkers, enhanced understanding of methylation dynamics and their impact on clinical outcomes.

Learning Objectives:

• Understand the role of methylation in human physiology
• Comprehend objective biomarkers of the methylation cycle, including the methylation ratio, methionine, SAM, SAH, homocysteine, cystathionine and cysteine
• Explore the clinical significance of methylation imbalances
• Discuss case applications and therapeutic strategies based on methylation status